{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:03Z","timestamp":1786980483887,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10067-020-05342-7","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T02:02:48Z","timestamp":1600048968000},"page":"1331-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-0913","authenticated-orcid":false,"given":"John D.","family":"Reveille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Danve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Hung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilianne","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K. H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"5342_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5371\/hp.2017.29.4.211","volume":"29","author":"Y Kim","year":"2017","unstructured":"Kim Y, Oh HC, Park JW, Kim IS, Kim JY, Kim KC, Chae DS, Jo WL, Song JH (2017) Diagnosis and treatment of inflammatory joint disease. Hip Pelvis 29:211\u2013222","journal-title":"Hip Pelvis"},{"key":"5342_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5114\/reum.2015.57634","volume":"53","author":"P Kawalec","year":"2015","unstructured":"Kawalec P, Malinowski K (2015) Disease activity, quality of life and indirect costs of reduced productivity at work, generated by polish patients with ankylosing spondylitis. Reumatologia 53:301\u2013308","journal-title":"Reumatologia"},{"key":"5342_CR3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/art.22887","volume":"57","author":"JC Davis Jr","year":"2007","unstructured":"Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57:1050\u20131057","journal-title":"Arthritis Rheum"},{"key":"5342_CR4","doi-asserted-by":"publisher","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","volume":"10","author":"R Cooksey","year":"2015","unstructured":"Cooksey R, Husain MJ, Brophy S, Davies H, Rahman MA, Atkinson MD, Phillips CJ, Siebert S (2015) The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. PLoS One 10:e0126105","journal-title":"PLoS One"},{"key":"5342_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/acr.22253","volume":"66","author":"VS Gordeev","year":"2014","unstructured":"Gordeev VS, Maksymowych WP, Schachna L, Boonen A (2014) Understanding presenteeism in patients with ankylosing spondylitis: contributing factors and association with sick leave. Arthritis Care Res (Hoboken) 66:916\u2013924","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5342_CR6","first-page":"1372","volume":"34","author":"R Escorpizo","year":"2007","unstructured":"Escorpizo R, Bombardier C, Boonen A, Hazes JM, Lacaille D, Strand V, Beaton D (2007) Worker productivity outcome measures in arthritis. J Rheumatol 34:1372\u20131380","journal-title":"J Rheumatol"},{"key":"5342_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","volume":"45","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2018) Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol 45:341\u2013348","journal-title":"J Rheumatol"},{"key":"5342_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3899\/jrheum.180718","volume":"46","author":"JD Reveille","year":"2019","unstructured":"Reveille JD, Deodhar A, Caldron PH, Dudek A, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2019) Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: results through 1 year of the GO-ALIVE study. J Rheumatol 46:1277\u20131283","journal-title":"J Rheumatol"},{"key":"5342_CR9","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876\u20131886","journal-title":"Arthritis Rheum"},{"key":"5342_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L (2019) 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71:1599\u20131613","journal-title":"Arthritis Rheumatol"},{"key":"5342_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"5342_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"LC Doward","year":"2003","unstructured":"Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwel PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA (2003) Development of ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20\u201326","journal-title":"Ann Rheum Dis"},{"key":"5342_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"5342_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43:203\u2013220","journal-title":"Med Care"},{"key":"5342_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15:708\u2013715","journal-title":"Value Health"},{"key":"5342_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00005650-200101000-00009","volume":"39","author":"D Lerner","year":"2001","unstructured":"Lerner D, Amick BC 3rd, Rogers WH, Malspeis S, Bungay K, Cynn D (2001) The work limitations questionnaire. Med Care 39:72\u201385","journal-title":"Med Care"},{"key":"5342_CR17","unstructured":"ASAS Group (2019) ASDAS calculator. ASDAS Group website. https:\/\/www.asas-group.org\/clinical-instruments\/asdas-calculator\/. Accessed on 20 July 2019"},{"key":"5342_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D, Assessment of SpondyloArthritis international Society (2011) Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47\u201353","journal-title":"Ann Rheum Dis"},{"key":"5342_CR19","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landew\u00e9 R, Assessment of SpondyloArthritis International Society (ASAS) (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811\u20131818","journal-title":"Ann Rheum Dis"},{"key":"5342_CR20","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing spondylitis disease activity index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"5342_CR21","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing spondylitis functional index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"5342_CR22","doi-asserted-by":"crossref","unstructured":"Ware JE Jr (2000) SF-36 health survey update. Spine (Phila Pa 1976) 25:3130\u20133139","DOI":"10.1097\/00007632-200012150-00008"},{"key":"5342_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12955-018-1055-z","volume":"16","author":"A Ousmen","year":"2018","unstructured":"Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, Br\u00e9dart A, Mollevi C, Anota A (2018) Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual Life Outcomes 16:228","journal-title":"Health Qual Life Outcomes"},{"key":"5342_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD (2011) Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 11:163\u2013169","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"5342_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-4-70","volume":"4","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK (2006) Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 4:70","journal-title":"Health Qual Life Outcomes"},{"key":"5342_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-015-0658-6","volume":"17","author":"SK Rai","year":"2015","unstructured":"Rai SK, Yazdany J, Fortin PR, Avi\u00f1a-Zubieta JA (2015) Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res Ther 17:143","journal-title":"Arthritis Res Ther"},{"key":"5342_CR27","unstructured":"Richard N, Haroon N, Tomlinson G, Sari I, Touma Z, Inman RD (2018) Establishing the minimal clinically important difference (MCID) for the ankylosing spondylitis quality of life questionnaire (ASQoL) [abstract]. Arthritis Rheumatol 70(suppl 10) https:\/\/acrabstracts.org\/abstract\/establishing-the-minimal-clinically-important-difference-mcid-for-the-ankylosing-spondylitis-quality-of-life-questionnaire-asqol\/. Accessed 15 January 2020"},{"key":"5342_CR28","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, Richards HB, Martin R, Porter B (2016) Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 68:2901\u20132910","journal-title":"Arthritis Rheumatol"},{"key":"5342_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/rheumatology\/ker404","volume":"51","author":"RJ Moots","year":"2012","unstructured":"Moots RJ, Ostor AJ, Loft AG, J\u00e4rvinen P, Larsson P, Ekelund M, Reynolds A, Kielar D, Lindkvist RM, Qvitzau S (2012) Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries. Rheumatology (Oxford) 51:393\u2013396","journal-title":"Rheumatology (Oxford)"},{"key":"5342_CR30","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1136\/annrheumdis-2012-201914","volume":"71","author":"LR van der Burg","year":"2012","unstructured":"van der Burg LR, Ter Wee MM, Boonen A (2012) Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review. Ann Rheum Dis 71:1924\u20131933","journal-title":"Ann Rheum Dis"},{"key":"5342_CR31","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1093\/rheumatology\/kex365","volume":"56","author":"M van Lunteren","year":"2017","unstructured":"van Lunteren M, Ez-Zaitouni Z, Fongen C, Landew\u00e9 R, Ramonda R, van der Heijde D, van Gaalen FA (2017) Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis caught early cohort). Rheumatology (Oxford) 56:2222\u20132228","journal-title":"Rheumatology (Oxford)"},{"key":"5342_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10067-008-1019-5","volume":"28","author":"R Ariza-Ariza","year":"2009","unstructured":"Ariza-Ariza R, Hern\u00e1ndez-Cruz B, L\u00f3pez-Antequera G, Navarro-Sarabia F (2009) Variables related to utility in patients with ankylosing spondylitis. Clin Rheumatol 28:207\u2013211","journal-title":"Clin Rheumatol"},{"key":"5342_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3899\/jrheum.090242","volume":"37","author":"WP Maksymowych","year":"2010","unstructured":"Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37:385\u2013392","journal-title":"J Rheumatol"},{"key":"5342_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D van der Heijde","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C, GO-RAISE investigators (2014) The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol 41:1095\u20131103","journal-title":"J Rheumatol"},{"key":"5342_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.vhri.2014.07.008","volume":"4","author":"K Kruntor\u00e1dov\u00e1","year":"2014","unstructured":"Kruntor\u00e1dov\u00e1 K, Klime\u0161 J, \u0160edov\u00e1 L, \u0160tolfa J, Dole\u017eal T, Pet\u0159ikov\u00e1 A (2014) Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Value Health Reg Issues 4:100\u2013106","journal-title":"Value Health Reg Issues"},{"key":"5342_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","volume":"55","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, Bao Y (2016) ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology (Oxford) 55:80\u201388","journal-title":"Rheumatology (Oxford)"},{"key":"5342_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"SA Pickard","year":"2019","unstructured":"Pickard SA, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschback JJV (2019) United States valuation of EQ-5D-5L health states using an international protocol. Value Health 22:931\u2013941","journal-title":"Value Health"},{"key":"5342_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P, Kavanaugh A, Kvien TK, Landew\u00e9 R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, de Wit M, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Cheng-Cheng Wei J, Winthrop K, van der Heijde D (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:6\u201316","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05342-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05342-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05342-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T20:05:37Z","timestamp":1631563537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05342-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5342"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05342-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"John D Reveille has received research grants from Eli Lilly and Company and Janssen and served as a consultant for Eli Lilly and Company, Novartis, Pfizer, and UCB. Mark C Hwang has received research grants from the NCATS\/UTHealth Center for Clinical and Translational Sciences KL2 program (1KL2-TR-003168-01). Abhijeet Danve has received research grants or served as a consultant or speaker for Janssen, Novartis, and Rockpointe Health. Shelly Kafka is an employee of Janssen Scientific Affairs, LLC and owns stock in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly owned subsidiary. Steven Peterson and Eric K H Chan are employees of Janssen Global Services, LLC and own stock in Johnson & Johnson, of which Janssen Global Services, LLC is a wholly owned subsidiary. Kim Hung Lo, Lilianne Kim, and Elizabeth C Hsia are employees of Janssen Research & Development, LLC and own stock in Johnson & Johnson, of which Janssen Research & Development is a wholly owned subsidiary. Atul Deodhar has received research grants from AbbVie Pharmaceuticals Inc., Eli Lilly and Company, GlaxoSmithKline, Janssen, Novartis, Pfizer, and UCB and served as a consultant or speaker for AbbVie Pharmaceuticals Inc., Amgen, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, and UCB. The authors have full control of all primary data and agree to allow the journal to review the data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}